Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Development and Validation of a Simplified Risk Score for the Prediction of Critical COVID-19 Illness in Newly Diagnosed Patients

Stanislas Werfel, Carolin E. M. Jakob, Stefan Borgmann, Jochen Schneider, Christoph Spinner, Maximilian Schons, Martin Hower, Kai Wille, Martina Haselberger, Hanno Heuzeroth, Maria M. Rüthrich, Sebastian Dolff, Johanna Kessel, Uwe Heemann, Jörg Janne Vehreschild, View ORCID ProfileSiegbert Rieg, Christoph Schmaderer on behalf of the LEOSS study group
doi: https://doi.org/10.1101/2021.02.07.21251260
Stanislas Werfel
1Department of Nephrology, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: christoph.schmaderer@mri.tum.de stanislas.werfel@tum.de
Carolin E. M. Jakob
2Department I for Internal Medicine, University Hospital of Cologne, University of Cologne, Cologne, Germany
3German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Borgmann
4Department of Infectious Diseases and Infection Control, Ingolstadt Hospital, Ingolstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jochen Schneider
5Technical University of Munich, School of Medicine, Department of Internal Medicine II, University hospital rechts der Isar, Munich, Germany
6German Center for Infection Research (DZIF), partner site Munich, Munich,Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Spinner
5Technical University of Munich, School of Medicine, Department of Internal Medicine II, University hospital rechts der Isar, Munich, Germany
6German Center for Infection Research (DZIF), partner site Munich, Munich,Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maximilian Schons
2Department I for Internal Medicine, University Hospital of Cologne, University of Cologne, Cologne, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Hower
7Department of Pneumology, Infectious Diseases and Internal Medicine Klinikum Dortmund gGmbH, Dortmund, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kai Wille
8University Clinic for Haematology, Oncology, Haemostaseology and Palliative Care,Johannes Wesling Medical Center Minden UKRUB, University of Bochum, Minden, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martina Haselberger
9Department of Internal Medicine I, Klinikum Passau, Passau, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanno Heuzeroth
10Department of Emergency and Intensive Care Medicine, Klinikum Ernst von Bergmann, Potsdam, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria M. Rüthrich
11Department of Internal Medicine II, Hematology and Medical Oncology, University Hospital Jena, Jena, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian Dolff
12Department of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, Essen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johanna Kessel
13Department of Internal Medicine, Hematology and Oncology, Goethe University Frankfurt, Frankfurt am Main, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Heemann
1Department of Nephrology, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jörg Janne Vehreschild
2Department I for Internal Medicine, University Hospital of Cologne, University of Cologne, Cologne, Germany
3German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany
13Department of Internal Medicine, Hematology and Oncology, Goethe University Frankfurt, Frankfurt am Main, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siegbert Rieg
14Department of Medicine II, University of Freiburg, Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Siegbert Rieg
Christoph Schmaderer
1Department of Nephrology, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: christoph.schmaderer@mri.tum.de stanislas.werfel@tum.de
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Scores for identifying patients at high risk of progression of the coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), are discussed as key instruments for clinical decision-making and patient management during the current pandemic.

Here we used the patient data from the multicenter Lean European Open Survey on SARS-CoV-2 - Infected Patients (LEOSS) and applied a technique of variable selection in order to develop a simplified score to identify patients at increased risk of critical illness or death.

A total of 1,946 patients, who were tested positive for SARS-CoV-2 were included in the initial analysis. They were split into a derivation and a validation cohort (n=1,297 and 649, respectively). A stability selection among a total of 105 baseline predictors for the combined endpoint of progression to critical phase or COVID-19-related death allowed us to develop a simplified score consisting of five predictors: CRP, Age, clinical disease phase (uncomplicated vs. complicated), serum urea and D-dimer (abbreviated as CAPS-D score). This score showed an AUC of 0.81 (CI95%: 0.77-0.85) in the validation cohort for predicting the combined endpoint within 7 days of diagnosis and 0.81 (CI95%: 0.77-0.85) during the full follow-up. Finally, we used an additional prospective cohort of 682 patients, who were diagnosed largely after the “first wave” of the pandemic to validate predictive accuracy of the score, observing similar results (AUC for an event within 7 days: 0.83, CI95%, 0.78-0.87; for full follow-up: 0.82, CI95%, 0.78-0.86).

We thus successfully establish and validate an easily applicable score to calculate the risk of disease progression of COVID-19 to critical illness or death.

Competing Interest Statement

Dr. Spinner reports grants, personal fees and non-financial support from Gilead Sciences, grants and personal fees from Janssen-Cilag, personal fees from Formycon, other from Aperion, other from Eli Lilly, during the conduct of the study; personal fees from AbbVie, personal fees from MSD, grants and personal fees from GSK/ViiV Healthcare, outside the submitted work. Dr. Ruethrich reports grants from IZKF, outside the submitted work. Dr. Vehreschild reports personal fees from Merck / MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), University Hospital Freiburg/ Congress and Communication, Academy for Infectious Medicine, University Manchester, German Society for Infectious Diseases (DGI), Aerztekammer Nordrhein, University Hospital Aachen, Back Bay Strategies, German Society for Internal Medicine (DGIM) and grants from Merck / MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), German Federal Ministry of Education and Research (BMBF), (PJ-T: DLR), University of Bristol, Rigshospitalet Copenhagen. All other authors report no conflicts of interest.

Clinical Trial

DRKS No. DRKS00021145

Funding Statement

The LEOSS registry was supported by the German Center for Infection Research (DZIF) and the Willy Robert Pitzer Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The current study received ethical approval by the ethics board of Klinikum rechts der Isar of the Technical University of Munich, Germany. Approval for LEOSS was obtained by the applicable local ethics committees of all participating centers. A list of all ethics votes is available at https://leoss.net/enrolled-sites-ethic-votes/.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Patient data from the LEOSS registry is subject to the LEOSS Governance, Data Use and Access Policy (policy text available on https://leoss.net).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted February 09, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Development and Validation of a Simplified Risk Score for the Prediction of Critical COVID-19 Illness in Newly Diagnosed Patients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Development and Validation of a Simplified Risk Score for the Prediction of Critical COVID-19 Illness in Newly Diagnosed Patients
Stanislas Werfel, Carolin E. M. Jakob, Stefan Borgmann, Jochen Schneider, Christoph Spinner, Maximilian Schons, Martin Hower, Kai Wille, Martina Haselberger, Hanno Heuzeroth, Maria M. Rüthrich, Sebastian Dolff, Johanna Kessel, Uwe Heemann, Jörg Janne Vehreschild, Siegbert Rieg, Christoph Schmaderer
medRxiv 2021.02.07.21251260; doi: https://doi.org/10.1101/2021.02.07.21251260
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Development and Validation of a Simplified Risk Score for the Prediction of Critical COVID-19 Illness in Newly Diagnosed Patients
Stanislas Werfel, Carolin E. M. Jakob, Stefan Borgmann, Jochen Schneider, Christoph Spinner, Maximilian Schons, Martin Hower, Kai Wille, Martina Haselberger, Hanno Heuzeroth, Maria M. Rüthrich, Sebastian Dolff, Johanna Kessel, Uwe Heemann, Jörg Janne Vehreschild, Siegbert Rieg, Christoph Schmaderer
medRxiv 2021.02.07.21251260; doi: https://doi.org/10.1101/2021.02.07.21251260

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (434)
  • Anesthesia (99)
  • Cardiovascular Medicine (948)
  • Dentistry and Oral Medicine (178)
  • Dermatology (110)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (422)
  • Epidemiology (8987)
  • Forensic Medicine (4)
  • Gastroenterology (420)
  • Genetic and Genomic Medicine (1959)
  • Geriatric Medicine (190)
  • Health Economics (402)
  • Health Informatics (1329)
  • Health Policy (660)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10809)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1830)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (353)
  • Occupational and Environmental Health (470)
  • Oncology (999)
  • Ophthalmology (298)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (580)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1903)
  • Public and Global Health (4123)
  • Radiology and Imaging (676)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (549)
  • Rheumatology (225)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (81)